Zhu Yihua, Cao XingJian, Lu Yonghui, Xu Dongsheng, Lu Renfei, Li Xinling
Clinical Laboratory, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
CBL Path Incorporated, Rye Brook, New York 10573, USA.
Cell Mol Biol (Noisy-le-grand). 2020 Oct 31;66(7):202-206.
The pandemic diseases caused by SARS-CoV-2 are now threatening human health and survival. Early diagnosis and isolation of mild or asymptomatic COVID-19 patients is important to control the spread of SARS-CoV-2. In this study, we investigate the potential clinical utility of lymphocyte CPD for early diagnosis of COVID-19. To investigate the potential of lymphocyte cell population data (lymphocyte CPD) for use in early diagnosis of coronavirus disease 2019 (COVID-19). Lymphocyte CPD of healthy control (n = 51), common cold patients (n = 49) and mild COVID-19 patients (n = 126) were generated using hematology analyzer. The parameters were subjected to sensitivity and specificity analysis to determine their suitability as biomarkers for early diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Normality analysis showed that lymphocyte CPD followed a normal distribution. There were no significant differences in white blood cells (WBC) and lymphocyte (LY#) counts as well as the neutrophil-to-lymphocyte ratio (NLR) among the groups (p > 0.05). Lymphocyte volume standard deviation (LV-SD), lymphocyte conductivity standard deviation (LC-SD) and lymphocyte light scatter standard deviation (LS-SD) were significantly higher in the COVID-19 group than in common cold and control groups (p < 0.05). The corresponding mean lymphocyte light scattering (MLS) was significantly reduced in the COVID-19 group, relative to the common cold group, but was significantly increased, when compared with the control group (p < 0.05). Moreover, there was no significant difference in mean lymphocyte volume (MLV) between the COVID-19 group and the common cold or control group (p > 0.05), but it was significantly higher in the common cold group than in the control group (p < 0.05). At a cutoff value ≥ 16.38, LS-SD was more sensitive and specific than other lymphocyte CPD parameters. At a cutoff value ≥ 11.89, LC-SD achieved 84.4 % sensitivity, 87.5 % specificity, and an area under the curve (AUC) of 0.888. However, at a cutoff value ≥ 15.95, LS-SD reached 81.3 % sensitivity, 75 % specificity and an AUC of 0.876. These results suggest that lymphocyte CPD parameters have great diagnostic potential for SARS-CoV-2 infection and can be used for early diagnosis of the disease.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的大流行疾病正威胁着人类健康与生存。对轻症或无症状2019冠状病毒病（COVID-19）患者进行早期诊断和隔离对于控制SARS-CoV-2的传播至关重要。在本研究中，我们探究了淋巴细胞综合参数诊断（CPD）在COVID-19早期诊断中的潜在临床应用价值。旨在研究淋巴细胞群体数据（淋巴细胞CPD）用于2019冠状病毒病（COVID-19）早期诊断的潜力。使用血液分析仪生成健康对照者（n = 51）、普通感冒患者（n = 49）和轻症COVID-19患者（n = 126）的淋巴细胞CPD。对这些参数进行敏感性和特异性分析，以确定它们作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染早期诊断生物标志物的适用性。正态性分析表明淋巴细胞CPD呈正态分布。各组间白细胞（WBC）、淋巴细胞计数（LY#）以及中性粒细胞与淋巴细胞比值（NLR）无显著差异（p＞0.05）。COVID-19组的淋巴细胞体积标准差（LV-SD）、淋巴细胞电导率标准差（LC-SD）和淋巴细胞光散射标准差（LS-SD）显著高于普通感冒组和对照组（p＜0.05）。COVID-19组的相应平均淋巴细胞光散射（MLS）相对于普通感冒组显著降低，但与对照组相比显著升高（p＜0.05）。此外，COVID-19组与普通感冒组或对照组之间的平均淋巴细胞体积（MLV）无显著差异（p＞0.05），但普通感冒组的MLV显著高于对照组（p＜0.05）。当截断值≥16.38时，LS-SD比其他淋巴细胞CPD参数更具敏感性和特异性。当截断值≥11.89时，LC-SD的敏感性为84.4%，特异性为87.5%，曲线下面积（AUC）为0.888。然而，当截断值≥15.95时，LS-SD的敏感性达到81.3%，特异性为75%，AUC为0.876。这些结果表明淋巴细胞CPD参数在SARS-CoV-2感染诊断方面具有巨大潜力，可用于该疾病的早期诊断。
